MediTrials OÜ
- Address
- L. Koidula Tn 5, 51006 Tartu, Estonia
MediTrials OÜ - Inflammatory Arthritis Research Center
MediTrials OÜ is a specialized clinical research center focused on advancing therapeutic options for patients with inflammatory rheumatic diseases. The center demonstrates particular expertise in evaluating novel biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for various forms of inflammatory arthritis, with emphasis on long-term safety and efficacy assessments.
- Psoriatic arthritis treatment studies including biologic therapies such as tildrakizumab
- Axial spondyloarthritis research evaluating JAK inhibitors and targeted immunomodulators
- Rheumatoid arthritis clinical trials comparing novel agents to standard-of-care therapies in methotrexate-inadequate responders
The research portfolio includes both pivotal Phase 3 comparative effectiveness trials and open-label extension studies designed to evaluate long-term safety profiles and sustained therapeutic responses. MediTrials OÜ's expertise encompasses comprehensive assessments using standardized outcome measures including American College of Rheumatology response criteria and structural progression monitoring, positioning the center as a key contributor to evidence-based advances in inflammatory arthropathy management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MediTrials OÜ
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2016-05-10 | 2016-05-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.